Roflumilast Cream for Residual Disease in Patients With Atopic Dermatitis on Dupilumab: A Retrospective Chart Review Study. [PDF]
Cutrona M, Golant AK.
europepmc +1 more source
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa +14 more
wiley +1 more source
Management of chronic urticaria: Current status and future prospect
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman +15 more
wiley +1 more source
Phenotype Switching in Pediatric Inflammatory Skin Diseases During Biologic Therapy: A Literature Review Focused on Atopic Dermatitis and Psoriasis. [PDF]
Tsai CF, Yu Y.
europepmc +1 more source
Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes +6 more
wiley +1 more source
Treatment Outcomes of Trichorrhexis Invaginata in SPINK5‐sEDD: A Systematic Review
ABSTRACT This systematic review evaluates treatment outcomes for trichorrhexis invaginata in SPINK5‐sEDD, formerly known as Netherton syndrome. SPINK5‐sEDD is a rare congenital disorder defined by ichthyosiform erythroderma, trichorrhexis invaginata, and atopy.
Katya Peri +8 more
wiley +1 more source
Dupilumab Improves Lung Function and Reduces Severe Exacerbations in Patients from China with Type 2 Asthma: A Subgroup Analysis of a Phase 3 Randomized Trial. [PDF]
Zhang Q +8 more
europepmc +1 more source
Successful treatment of Hailey–Hailey disease (HHD) with the IL‐13 inhibitor lebrikizumab
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Elena Schneider +3 more
wiley +1 more source
ABSTRACT Background/Objective The multifactorial disease burden of moderate‐to‐severe atopic dermatitis (AD) may affect children's growth. We report height, weight, and body mass index (BMI) of children under 12 years old with moderate‐to‐severe AD in comparison to the general population.
Amy S. Paller +11 more
wiley +1 more source
Sustained Remission Following Limited Dupilumab Exposure in Refractory Eosinophilic Esophagitis. [PDF]
Kim DR, Bubelenyi A, Gupta M.
europepmc +1 more source

